HPV vaccination programme: change from 3 to 2 doses
This letter provides information on forthcoming changes to the human papillomavirus (HPV) vaccine programme.
Documents
Details
In March 2014, the Joint Committee on Vaccination and Immunisation (JCVI) revised its existing recommendation to change from a 3 to a 2 dose schedule. Recent research shows that antibody response to 2 doses in adolescent girls is as good as a 3 dose course in the age group where efficacy against persistent infection and pre-cancerous lesions has been demonstrated.
Emerging evidence from evaluation of HPV programmes around the world has shown that the number of young people with pre-cancerous lesions is falling and protection is expected to be long term.